公开(公告)号：US20150329499A1

公开(公告)日：2015-11-19

申请号：US14651777

申请日：2013-12-13

Applicant: UNIVERSITY OF KANSAS ,  UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. ,  SOUTHERN RESEARCH INSTITUTE

Inventor： Jennifer Golden ,  Jeffrey Aube ,  Donghoon Chung ,  Chad Schroeder ,  Tuanli Yao ,  E. Lucile White ,  Nichole A. Tower

IPC: C07D241/06

CPC classification number: C07D409/04 ,  C07D239/90 ,  C07D239/91 ,  C07D239/95 ,  C07D241/06 ,  C07D401/04 ,  C07D403/06 ,  C07D403/12 ,  C07D409/12

Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).

Abstract translation: 本技术涉及式I-III的化合物和组合物以及使用这些化合物的方法。 本文所述的化合物和组合物可用于治疗或预防与甲病毒属例如委内瑞兰马脑炎病毒（VEEV）相关的疾病。

公开(公告)号：US20150203477A1

公开(公告)日：2015-07-23

申请号：US14408736

申请日：2013-06-18

Applicant: University of Kansas ,  The Regents of the University of Michigan ,  Wayne State University ,  Sanford-Burnham Medical Research Institute

Inventor： Jennifer E. Golden ,  Jeffrey Aube ,  Daniel P. Flaherty ,  Andrew M. Fribley ,  Randal J. Kaufman ,  Thomas D.Y. Chung ,  Anthony B. Pinkerton ,  Michael Pablo Hedrick

IPC: C07D405/12 ,  C07C303/36 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/496 ,  C07D307/71 ,  A61K31/4525

CPC classification number: C07D405/12 ,  A61K31/4525 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07C303/36 ,  C07D307/71

Abstract: N-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provides as is their use in the treatment of diseases such as diabetes, Alzheimer's, Parkinson's, hemophilia, lysosomal storage diseases and cancer.

Abstract translation: N-取代的磺酰基苯基-5-硝基呋喃-2-甲酰胺衍生化合物，其选择性地激活未折叠蛋白质反应的凋亡但不适应臂，其用途可用于治疗疾病如糖尿病，阿尔茨海默氏症，帕金森病 ，血友病，溶酶体贮积病和癌症。

公开(公告)号：US10787439B2

公开(公告)日：2020-09-29

申请号：US15672574

申请日：2017-08-09

Applicant: University of Kansas ,  The Regents of the University of Michigan ,  Wayne State University ,  Sanford-Burnham Medical Research Institute

Inventor： Jennifer E. Golden ,  Jeffrey Aube ,  Daniel P. Flaherty ,  Andrew M. Fribley ,  Randal J. Kaufman ,  Thomas D. Y. Chung ,  Anthony B. Pinkerton ,  Michael Pablo Hedrick

IPC: A61K31/4525 ,  C07D405/12 ,  C07D307/71 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07C303/36

Abstract: N-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provides as is their use in the treatment of diseases such as diabetes, Alzheimer's, Parkinson's, hemophilia, lysosomal storage diseases and cancer.

公开(公告)号：US10532999B2

公开(公告)日：2020-01-14

申请号：US16149009

申请日：2018-10-01

Applicant: University of Kansas ,  University of Louisville Research Foundation, Inc. ,  Southern Research Institute

Inventor： Jennifer Golden ,  Jeffrey Aube ,  Donghoon Chung ,  Chad Schroeder ,  Tuanli Yao ,  E. Lucile White ,  Nichole A. Tower

IPC: C07D409/04 ,  C07D239/95 ,  C07D409/12 ,  C07D403/06 ,  C07D401/04 ,  C07D239/91 ,  C07D239/90 ,  C07D403/12 ,  C07D241/06

Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).

公开(公告)号：US20190270730A1

公开(公告)日：2019-09-05

申请号：US16149009

申请日：2018-10-01

Applicant: University of Kansas ,  University of Louisville Research Foundation, Inc. ,  Southern Research Institute

Inventor： Jennifer Golden ,  Jeffrey Aube ,  Donghoon Chung ,  Chad Schroeder ,  Tuanli Yao ,  E. Lucile White ,  Nichole A. Tower

IPC: C07D409/04 ,  C07D239/95 ,  C07D409/12 ,  C07D403/06 ,  C07D241/06 ,  C07D239/91 ,  C07D239/90 ,  C07D403/12 ,  C07D401/04

Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).

公开(公告)号：US20170260141A1

公开(公告)日：2017-09-14

申请号：US15529290

申请日：2015-11-25

Applicant: University of Kansas

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D223/16 ,  C07D209/44

CPC classification number: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

公开(公告)号：US09499496B2

公开(公告)日：2016-11-22

申请号：US14405772

申请日：2013-06-05

Applicant: University of Kansas ,  Southern Research Institute

Inventor： Jennifer E. Golden ,  Jeffrey Aube ,  Denise S. Simpson ,  Daniel P. Flaherty ,  Daljit S. Matharu ,  William E. Severson ,  Lynn Rasmussen

IPC: C07D239/96 ,  C07D405/12 ,  C12N7/00 ,  A61K31/517

CPC classification number: C07D239/96 ,  A61K31/517 ,  C07D405/12 ,  C12N7/00 ,  C12N2760/18563

Abstract: Described herein are compounds, pharmaceutical compositions and methods for treating a respiratory syncytial virus infection in a subject, or for inhibiting replication of respiratory syncytial virus.

Abstract translation: 本文描述了用于治疗受试者中呼吸道合胞病毒感染或抑制呼吸道合胞病毒复制的化合物，药物组合物和方法。

公开(公告)号：US20160257685A1

公开(公告)日：2016-09-08

申请号：US15156887

申请日：2016-05-17

Applicant: University of Kansas ,  The Scripps Research Institute

Inventor： Jeffrey Aube ,  Laura Bohn ,  Thomas Edward Prisinzano ,  Frank John Schoenen ,  Kevin J. Frankowski

IPC: C07D471/14 ,  C07D401/14 ,  C07D409/14 ,  C07D401/04 ,  C07D471/04 ,  C07D405/14

CPC classification number: C07D471/14 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  A61K2300/00

Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.

Abstract translation: 本发明是可用于治疗乙醇使用障碍戒断，焦虑和/或抑郁，精神分裂症，躁狂症或创伤后应激障碍的选择性κ阿片受体效应物或其药学上可接受的盐。

公开(公告)号：US10829453B2

公开(公告)日：2020-11-10

申请号：US16179637

申请日：2018-11-02

Applicant: University of Kansas ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

公开(公告)号：US20190300486A1

公开(公告)日：2019-10-03

申请号：US16179637

申请日：2018-11-02

Applicant: University of Kansas ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.